Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Regarding vitamin D (25-OHD), White participants had the highest levels, with a statistically significant difference compared with all other ethnicities (P < .0001).
Source: Multi-ethnic variations in CKD-MBD markers. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Secondary analysis.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were invited by their usual nephrologist to participate in this study.
Source: Methods.
Additional written informed consent was not obtained for this post hoc analysis.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease-mineral and bone disorder
Secondary analysis · Clinical Kidney Journal · 2024
Original publication title
Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease: mineral and bone disorder
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Fibroblast growth factor 23 (FGF-23) and other markers of chronic kidney disease: mineral and bone disorder (CKD-MBD) provide valuable insights into disease processes, treatment options and patient prognosis. However, limited research has explored potential associations with ethnicity or season, particularly in multi-ethnic populations residing in high-latitude regions.
Source: BackgroundAbstract: What methods does the paper describe?
We evaluated CKD-BMD markers in a diverse cohort of CKD patients, who were participants of The CANADIAN AIM to PREVENT (the CAN AIM to PREVENT) study. FGF-23, calcium, phosphate, 25-hydroxyvitamin D (25-OHD) and intact parathyroid hormone (iPTH) in 1234 participants with pre-dialysis CKD (mean estimated glomerular filtration rate: 41.8 ± 14.3 mL/min) were analyzed. Mixed-effects general linear regression models adjusted for demographic and biological factors were used to compare repeated measurements across patient groups categorized by ethnicity (East Asian, White, South Asian, Black, Southeast Asian) and seasons.
Source: MethodsAbstract: Results
Compared with other groups, White participants exhibited 8.0%: 18.5% higher FGF-23 levels, Black participants had 0.17 to 0.32 mg/dL higher calcium levels, White participants had 10.0%: 20.1% higher 25-OHD levels, South Asian participants had 7.3%: 20.1% lower 25-OHD levels and Black participants had 22.1 to 73.8% higher iPTH levels, while East Asian participants had 10.7%: 73.8% lower iPTH levels. Seasonal variations were also observed. FGF-23 levels were 11.9%: 15.5% higher in summer compared with other seasons, while calcium levels were 0.03 to 0.06 mg/dL lower in summer. 25-OHD levels were 5.6%: 10.6% higher in summer and autumn compared with other seasons.
Source: ResultsAbstract: Conclusions
This study shows that FGF-23 and CKD-MBD markers in a Canadian pre-dialysis CKD cohort vary independently by ethnicity and season. Further research is needed to understand the reasons and clinical significance of these findings.
Source: ConclusionsAuthors’ abstract
ABSTRACT
Background
Fibroblast growth factor 23 (FGF-23) and other markers of chronic kidney disease: mineral and bone disorder (CKD-MBD) provide valuable insights into disease processes, treatment options and patient prognosis. However, limited research has explored potential associations with ethnicity or season, particularly in multi-ethnic populations residing in high-latitude regions.
Methods
We evaluated CKD-BMD markers in a diverse cohort of CKD patients, who were participants of The CANADIAN AIM to PREVENT (the CAN AIM to PREVENT) study. FGF-23, calcium, phosphate, 25-hydroxyvitamin D (25-OHD) and intact parathyroid hormone (iPTH) in 1234 participants with pre-dialysis CKD (mean estimated glomerular filtration rate: 41.8 ± 14.3 mL/min) were analyzed. Mixed-effects general linear regression models adjusted for demographic and biological factors were used to compare repeated measurements across patient groups categorized by ethnicity (East Asian, White, South Asian, Black, Southeast Asian) and seasons.
Results
Compared with other groups, White participants exhibited 8.0%: 18.5% higher FGF-23 levels, Black participants had 0.17 to 0.32 mg/dL higher calcium levels, White participants had 10.0%: 20.1% higher 25-OHD levels, South Asian participants had 7.3%: 20.1% lower 25-OHD levels and Black participants had 22.1 to 73.8% higher iPTH levels, while East Asian participants had 10.7%: 73.8% lower iPTH levels. Seasonal variations were also observed. FGF-23 levels were 11.9%: 15.5% higher in summer compared with other seasons, while calcium levels were 0.03 to 0.06 mg/dL lower in summer. 25-OHD levels were 5.6%: 10.6% higher in summer and autumn compared with other seasons.
Conclusions
This study shows that FGF-23 and CKD-MBD markers in a Canadian pre-dialysis CKD cohort vary independently by ethnicity and season. Further research is needed to understand the reasons and clinical significance of these findings.
Publication and source details
Original title: Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease: mineral and bone disorder
Hulya Taskapan; Sara Mahdavi; Antonio Bellasi; Salome Martin; Saeeda Kuvadia; Anfal Patel; Berkay Taskapan; Paul Tam; Tabo Sikaneta
Clinical Kidney Journal · 2024
Correspondence to: Tabo Sikaneta; E-mail: tsikaneta@shn.ca© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.2024https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:59:32.504710+00:00
DOI: 10.1093/ckj/sfae188 · PMC11273220